- Home
- HTCR vs APVO Comparison
HTCR vs APVO Comparison
Compare HTCR & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTCR
- APVO
- Stock Information
- Founded
- HTCR 2009
- APVO 2016
- Country
- HTCR Japan
- APVO United States
- Employees
- HTCR N/A
- APVO N/A
- Industry
- HTCR EDP Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- HTCR Technology
- APVO Health Care
- Exchange
- HTCR Nasdaq
- APVO Nasdaq
- Market Cap
- HTCR 21.2M
- APVO 21.7M
- IPO Year
- HTCR 2022
- APVO N/A
- Fundamental
- Price
- HTCR $0.75
- APVO $1.53
- Analyst Decision
- HTCR
- APVO
- Analyst Count
- HTCR 0
- APVO 0
- Target Price
- HTCR N/A
- APVO N/A
- AVG Volume (30 Days)
- HTCR 2.5M
- APVO 4.6M
- Earning Date
- HTCR 11-13-2025
- APVO 11-10-2025
- Dividend Yield
- HTCR N/A
- APVO N/A
- EPS Growth
- HTCR N/A
- APVO N/A
- EPS
- HTCR N/A
- APVO N/A
- Revenue
- HTCR $29,625,381.00
- APVO N/A
- Revenue This Year
- HTCR N/A
- APVO N/A
- Revenue Next Year
- HTCR $3.52
- APVO N/A
- P/E Ratio
- HTCR N/A
- APVO N/A
- Revenue Growth
- HTCR 72.95
- APVO N/A
- 52 Week Low
- HTCR $0.39
- APVO $1.32
- 52 Week High
- HTCR $3.38
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- HTCR 44.23
- APVO 45.02
- Support Level
- HTCR $0.68
- APVO $1.48
- Resistance Level
- HTCR $0.90
- APVO $1.65
- Average True Range (ATR)
- HTCR 0.08
- APVO 0.13
- MACD
- HTCR -0.01
- APVO 0.01
- Stochastic Oscillator
- HTCR 26.84
- APVO 20.18
About HTCR Heartcore Enterprises Inc.
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.